Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL J GOLDSTEIN

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1063410645
CMS profile
2193
Location
GREAT NECK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$622.74

34 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $622.74 34

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL J GOLDSTEIN

NPI 1063410645 · CMS profile ID 2193

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

GREAT NECK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1063410645?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL J GOLDSTEIN, NPI 1063410645, CMS profile ID 2193. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1063410645?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MICHAEL J GOLDSTEIN, NPI 1063410645, CMS profile ID 2193. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1063410645?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MICHAEL J GOLDSTEIN, NPI 1063410645, CMS profile ID 2193, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1063410645?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

34 matching records · $622.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 34 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–34 of 34.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $14.4012/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681519493 CMS
Merck Sharp & Dohme Corporation $16.6612/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695877183 CMS
Merck Sharp & Dohme Corporation $16.4111/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695840905 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $22.8611/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684738533 CMS
Ironwood Pharmaceuticals, Inc $18.9111/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709213297 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $19.2611/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684738531 CMS
Merck Sharp & Dohme Corporation $15.9611/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695872097 CMS
Ironwood Pharmaceuticals, Inc $22.3810/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709213299 CMS
Daiichi Sankyo Inc. $24.3210/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695371037 CMS
Merck Sharp & Dohme Corporation $15.6509/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695752769 CMS
PFIZER INC. $21.8809/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673838787 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $24.0009/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684738529 CMS
Ferring Pharmaceuticals Inc. $20.6808/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655190025 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $18.1607/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684738527 CMS
Ferring Pharmaceuticals Inc. $16.2506/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655190023 CMS
Merck Sharp & Dohme Corporation $14.0706/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695679447 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.7106/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684738525 CMS
Merck Sharp & Dohme Corporation $19.7105/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695481359 CMS
Daiichi Sankyo Inc. $17.2305/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695323117 CMS
Ferring Pharmaceuticals Inc. $20.9605/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655190021 CMS
Takeda Pharmaceuticals U.S.A., Inc. $21.6005/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681725955 CMS
Ironwood Pharmaceuticals, Inc $16.6304/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709213301 CMS
Merck Sharp & Dohme Corporation $19.1804/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695446827 CMS
Gilead Sciences, Inc. $13.1304/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681519491 CMS
Ironwood Pharmaceuticals, Inc $15.5703/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709213303 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $0.8602/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684738521 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $19.5002/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684738523 CMS
Janssen Biotech, Inc. $22.1402/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658449965 CMS
Ferring Pharmaceuticals Inc. $16.7102/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655190019 CMS
Daiichi Sankyo Inc. $24.6802/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695301259 CMS
PFIZER INC. $16.8201/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671895557 CMS
Ironwood Pharmaceuticals, Inc $19.2101/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709213305 CMS
PFIZER INC. $19.8001/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671849153 CMS
Ferring Pharmaceuticals Inc. $22.4501/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655190017 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $622.74 34
PY2020 $554.05 32
PY2021 $303.05 16
PY2022 $155.50 9
PY2023 $187.37 4
PY2025 $267.73 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $88,071.47 22
PY2023 Principal investigator $169,779.57 14
PY2022 Principal investigator $32,010.78 12
PY2021 Recipient $3,971.40 2
PY2021 Principal investigator $162,998.92 79
PY2020 Principal investigator $489,931.11 140
PY2019 Recipient $883.66 5
PY2019 Principal investigator $583,175.74 159

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

164 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $8,963.07 12/31/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670120407
Principal investigator 1 Allergan Inc. $2,261.26 12/31/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure No dispute reported 06/30/2026 670124565
Principal investigator 1 Allergan Inc. $14,764.85 12/31/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670124727
Principal investigator 1 Allergan Inc. $601.63 12/31/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis DG No dispute reported 06/30/2026 670126977
Principal investigator 1 Allergan Inc. $700.00 12/17/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670114301
Principal investigator 1 Allergan Inc. $1,064.00 12/16/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670111193
Principal investigator 1 Allergan Inc. $1,018.50 12/16/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis DG No dispute reported 06/30/2026 670111423
Principal investigator 1 Allergan Inc. $11,381.00 12/16/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670111490
Principal investigator 1 Allergan Inc. $13,718.00 12/16/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670113279
Principal investigator 1 Ironwood Pharmaceuticals, Inc $72.50 12/10/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
MCP-103-205 No dispute reported 06/30/2026 705397395
Principal investigator 1 Ironwood Pharmaceuticals, Inc $350.00 12/10/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
MCP-103-205 No dispute reported 06/30/2026 705397397
Principal investigator 1 Allergan Inc. $700.00 12/05/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
OPEN-LABEL EXTENSION STUDY OF RELAMORELIN FOR THE TREATMENT OF DIABETIC GASTROPARESIS DG No dispute reported 06/30/2026 670106407
Principal investigator 1 Ironwood Pharmaceuticals, Inc $7,012.50 12/05/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
MCP-103-205 No dispute reported 06/30/2026 705397399
Principal investigator 1 Allergan Inc. $2,000.00 12/01/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670104811
Principal investigator 1 Allergan Inc. $2,000.00 12/01/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670105001
Principal investigator 1 Allergan Inc. $115.00 11/19/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670099573
Principal investigator 1 Allergan Inc. $115.00 11/19/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670099853
Principal investigator 1 Allergan Inc. $115.00 11/19/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670100103
Principal investigator 1 Allergan Inc. $955.00 11/19/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670100653
Principal investigator 1 Allergan Inc. $115.00 11/19/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670100747
Principal investigator 1 Allergan Inc. $14,364.00 11/19/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670102325
Principal investigator 1 Shire North American Group Inc $11,210.40 11/14/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, MAINTENANCE No dispute reported 06/30/2026 637715269
Principal investigator 1 Ironwood Pharmaceuticals, Inc $160.00 11/13/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397383
Principal investigator 1 Ironwood Pharmaceuticals, Inc $250.00 11/13/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397385
Principal investigator 1 Ironwood Pharmaceuticals, Inc $250.00 11/13/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397387
Principal investigator 1 Braintree Laboratories, Inc. $3,500.00 11/07/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTENSTINAL RESEARCH GROUP
BLI800-491 No dispute reported 06/30/2026 703850245
Principal investigator 1 Allergan Inc. $70.00 11/01/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670093927
Principal investigator 1 Ironwood Pharmaceuticals, Inc $13,148.75 11/01/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
MCP-103-205 No dispute reported 06/30/2026 705397393
Principal investigator 1 Allergan Inc. $2,014.00 10/29/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670092227
Principal investigator 1 Shire North American Group Inc $2,851.20 10/24/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, MAINTENANCE No dispute reported 06/30/2026 637714615
Principal investigator 1 Ironwood Pharmaceuticals, Inc $350.00 10/22/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
MCP-103-205 No dispute reported 06/30/2026 705397389
Principal investigator 1 Ironwood Pharmaceuticals, Inc $20,630.00 10/16/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397391
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,250.00 10/11/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis EoE No dispute reported 06/30/2026 639742839
Principal investigator 1 Allergan Inc. $2,000.00 10/10/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670084391
Principal investigator 1 Allergan Inc. $2,299.00 10/09/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670083837
Principal investigator 1 Allergan Inc. $10,773.00 10/07/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670082517
Principal investigator 1 Adare Pharmaceuticals, Inc. $12,250.00 10/02/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
SP-1011-002 No dispute reported 06/30/2026 704669271
Principal investigator 1 Allergan Inc. $3,055.50 10/02/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis DG No dispute reported 06/30/2026 670081805
Principal investigator 1 Allergan Inc. $2,000.00 10/01/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670081195
Principal investigator 1 Allergan Inc. $2,000.00 10/01/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670081221
Principal investigator 1 Allergan Inc. $2,000.00 10/01/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670081245
Principal investigator 1 Allergan Inc. $2,000.00 10/01/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670081651
Principal investigator 1 Shire North American Group Inc $3,599.80 10/01/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
CONTINUATION STUDY WITH BUDESONIDE ORAL SUSPENSION BOS FOR ADOLESCENT AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS EOE No dispute reported 06/30/2026 637714095
Principal investigator 1 Ironwood Pharmaceuticals, Inc $11.73 09/27/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397369
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,499.00 09/25/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis EoE No dispute reported 06/30/2026 639742837
Principal investigator 1 Ironwood Pharmaceuticals, Inc $415.00 09/20/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
MCP-103-312 No dispute reported 06/30/2026 705397307
Principal investigator 1 Ironwood Pharmaceuticals, Inc $250.00 09/20/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397367
Principal investigator 1 Ironwood Pharmaceuticals, Inc $160.00 09/18/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397361
Principal investigator 1 Ironwood Pharmaceuticals, Inc $160.00 09/18/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397363
Principal investigator 1 Ironwood Pharmaceuticals, Inc $32,410.00 09/18/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397365
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $600.00 09/17/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis No dispute reported 06/30/2026 686167867
Principal investigator 1 Shire North American Group Inc $222.00 09/12/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
CONTINUATION STUDY WITH BUDESONIDE ORAL SUSPENSION BOS FOR ADOLESCENT AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS EOE No dispute reported 06/30/2026 637713857
Principal investigator 1 Ironwood Pharmaceuticals, Inc $322.50 09/11/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397359
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $50.00 09/10/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis No dispute reported 06/30/2026 686167869
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $150.00 09/10/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis No dispute reported 06/30/2026 686167871
Principal investigator 1 Allergan Inc. $1,720.00 09/04/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670072845
Principal investigator 1 Allergan Inc. $140.00 09/01/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis DG No dispute reported 06/30/2026 670071583
Principal investigator 1 Allergan Inc. $18,620.00 08/30/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670070889
Principal investigator 1 Allergan Inc. $950.00 08/29/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670070785
Principal investigator 1 Shire North American Group Inc $222.00 08/27/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
CONTINUATION STUDY WITH BUDESONIDE ORAL SUSPENSION BOS FOR ADOLESCENT AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS EOE No dispute reported 06/30/2026 637713565
Principal investigator 1 Shire North American Group Inc $2,013.60 08/27/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
CONTINUATION STUDY WITH BUDESONIDE ORAL SUSPENSION BOS FOR ADOLESCENT AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS EOE No dispute reported 06/30/2026 637713567
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $600.00 08/27/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis No dispute reported 06/30/2026 686167863
Principal investigator 1 Allergan Inc. $1,435.00 08/23/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure No dispute reported 06/30/2026 670069451
Principal investigator 1 Shire North American Group Inc $104.47 08/15/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, MAINTENANCE No dispute reported 06/30/2026 637713407
Principal investigator 1 Ironwood Pharmaceuticals, Inc $996.00 08/14/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
MCP-103-312 No dispute reported 06/30/2026 705397305
Principal investigator 1 Allergan Inc. $3,268.00 08/13/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670064963
Principal investigator 1 Allergan Inc. $2,000.00 08/12/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670064307
Principal investigator 1 Ironwood Pharmaceuticals, Inc $150.00 08/06/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
MD-7246_MCP103-205 No dispute reported 06/30/2026 705397377
Principal investigator 1 Shire North American Group Inc $3,303.60 08/06/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, MAINTENANCE No dispute reported 06/30/2026 637713129
Principal investigator 1 Allergan Inc. $2,000.00 08/01/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670062555
Principal investigator 1 Allergan Inc. $2,000.00 08/01/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670062669
Principal investigator 1 Allergan Inc. $2,000.00 08/01/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670062685
Principal investigator 1 Allergan Inc. $500.00 08/01/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670063153
Principal investigator 1 Allergan Inc. $989.40 07/30/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis DG No dispute reported 06/30/2026 670061855
Principal investigator 1 Ironwood Pharmaceuticals, Inc $11.71 07/26/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397355
Principal investigator 1 Ironwood Pharmaceuticals, Inc $18.74 07/26/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397357
Principal investigator 1 Allergan Inc. $1,833.50 07/25/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670060843
Principal investigator 1 Ironwood Pharmaceuticals, Inc $53,142.50 07/19/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397353
Principal investigator 1 Allergan Inc. $3,268.00 07/16/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670057987
Principal investigator 1 Allergan Inc. $2,622.00 07/16/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure No dispute reported 06/30/2026 670058031
Principal investigator 1 Allergan Inc. $1,634.00 07/16/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670058085
Principal investigator 1 Ironwood Pharmaceuticals, Inc $30.89 07/15/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397345
Principal investigator 1 Ironwood Pharmaceuticals, Inc $37.50 07/15/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397347
Principal investigator 1 Ironwood Pharmaceuticals, Inc $160.00 07/15/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397349
Principal investigator 1 Ironwood Pharmaceuticals, Inc $160.00 07/15/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397351
Principal investigator 1 Allergan Inc. $1,018.50 07/12/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis DG No dispute reported 06/30/2026 670056539
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,261.26 07/10/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis EoE No dispute reported 06/30/2026 639742835
Principal investigator 1 Shire North American Group Inc $105.39 07/09/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, MAINTENANCE No dispute reported 06/30/2026 637712341
Principal investigator 1 Adare Pharmaceuticals, Inc. $1,036.00 07/08/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
SP-1011-002 No dispute reported 06/30/2026 704669085
Principal investigator 1 Adare Pharmaceuticals, Inc. $956.00 07/08/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
SP-1011-002 No dispute reported 06/30/2026 704669087
Principal investigator 1 Adare Pharmaceuticals, Inc. $462.00 07/08/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
SP-1011-002 No dispute reported 06/30/2026 704669089
Principal investigator 1 Ironwood Pharmaceuticals, Inc $996.00 07/01/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
MD-7246_MCP103-205 No dispute reported 06/30/2026 705397375
Principal investigator 1 Shire North American Group Inc $2,993.20 06/13/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, MAINTENANCE No dispute reported 06/30/2026 637711863
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $175.00 06/10/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis EoE No dispute reported 06/30/2026 639742833
Principal investigator 1 Shire North American Group Inc $2,851.20 06/04/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, MAINTENANCE No dispute reported 06/30/2026 637711609
Principal investigator 1 Allergan Inc. $150.00 05/23/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH G
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670047523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $55.45 05/22/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis EoE No dispute reported 06/30/2026 639742831
Principal investigator 1 Ironwood Pharmaceuticals, Inc $1,665.00 05/21/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
MD-7246_MCP103-205 No dispute reported 06/30/2026 705397371
Principal investigator 1 Ironwood Pharmaceuticals, Inc $3,100.00 05/21/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
MD-7246_MCP103-205 No dispute reported 06/30/2026 705397373
Recipient Regeneron Pharmaceuticals, Inc. $160.00 05/21/2019 Covered Recipient Physician A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis EoE No dispute reported 06/30/2026 639752101
Principal investigator 1 Shire North American Group Inc $10,772.40 05/21/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, MAINTENANCE No dispute reported 06/30/2026 637711427
Principal investigator 1 Shire North American Group Inc $67.20 05/16/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, MAINTENANCE No dispute reported 06/30/2026 637711343
Principal investigator 1 Allergan Inc. $1,634.00 05/15/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670045667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,500.00 05/15/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis EoE No dispute reported 06/30/2026 639742829
Principal investigator 1 Ironwood Pharmaceuticals, Inc $7,511.25 05/08/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
MCP-103-312 No dispute reported 06/30/2026 705397303
Principal investigator 1 Shire North American Group Inc $3,343.20 05/07/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, PLACEBO-CONTROLLED, RW No dispute reported 06/30/2026 637711139
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,700.00 05/07/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis No dispute reported 06/30/2026 686167865
Recipient Regeneron Pharmaceuticals, Inc. $283.61 05/04/2019 Covered Recipient Physician A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis EoE No dispute reported 06/30/2026 639752095
Recipient Regeneron Pharmaceuticals, Inc. $206.30 05/04/2019 Covered Recipient Physician A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis EoE No dispute reported 06/30/2026 639752097
Recipient Regeneron Pharmaceuticals, Inc. $130.00 05/04/2019 Covered Recipient Physician A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis EoE No dispute reported 06/30/2026 639752099
Principal investigator 1 Ironwood Pharmaceuticals, Inc $250.00 05/03/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397341
Principal investigator 1 Ironwood Pharmaceuticals, Inc $1,843.75 05/03/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397343
Recipient Regeneron Pharmaceuticals, Inc. $103.75 05/03/2019 Covered Recipient Physician A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis EoE No dispute reported 06/30/2026 639752093
Principal investigator 1 Allergan Inc. $1,957.00 05/01/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670042651
Principal investigator 1 Allergan Inc. $1,363.25 05/01/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure No dispute reported 06/30/2026 670042693
Principal investigator 1 Allergan Inc. $1,634.00 05/01/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670042707
Principal investigator 1 Shire North American Group Inc $82.35 05/01/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, MAINTENANCE No dispute reported 06/30/2026 637710915
Principal investigator 1 Shire North American Group Inc $93.73 05/01/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, MAINTENANCE No dispute reported 06/30/2026 637710917
Principal investigator 1 Allergan Inc. $6,441.00 04/30/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670042583
Principal investigator 1 Ironwood Pharmaceuticals, Inc $300.00 04/26/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397335
Principal investigator 1 Allergan Inc. $450.00 04/23/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH G
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 670040427
Principal investigator 1 Ironwood Pharmaceuticals, Inc $87,812.50 04/17/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397333
Principal investigator 1 Shire North American Group Inc $8.64 04/11/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, MAINTENANCE No dispute reported 06/30/2026 637710297
Principal investigator 1 Shire North American Group Inc $302.40 04/11/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, MAINTENANCE No dispute reported 06/30/2026 637710299
Principal investigator 1 Ironwood Pharmaceuticals, Inc $390.00 04/10/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397331
Principal investigator 1 Ironwood Pharmaceuticals, Inc $11.61 04/05/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397337
Principal investigator 1 Ironwood Pharmaceuticals, Inc $39.12 04/05/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397339
Principal investigator 1 Ironwood Pharmaceuticals, Inc $315.00 03/27/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
MCP-103-312 No dispute reported 06/30/2026 705397297
Principal investigator 1 Ironwood Pharmaceuticals, Inc $455.00 03/27/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
MCP-103-312 No dispute reported 06/30/2026 705397299
Principal investigator 1 Ironwood Pharmaceuticals, Inc $520.00 03/27/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
MCP-103-312 No dispute reported 06/30/2026 705397301
Principal investigator 1 Shire North American Group Inc $186.00 03/26/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, PLACEBO-CONTROLLED, RW No dispute reported 06/30/2026 637709933
Principal investigator 1 Shire North American Group Inc $259.20 03/26/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, PLACEBO-CONTROLLED, RW No dispute reported 06/30/2026 637709935
Principal investigator 1 Shire North American Group Inc $222.00 03/26/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, MAINTENANCE No dispute reported 06/30/2026 637709953
Principal investigator 1 Ironwood Pharmaceuticals, Inc $160.00 03/22/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397329
Principal investigator 1 Allergan Inc. $61.45 03/19/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH G
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 670031653
Principal investigator 1 Shire North American Group Inc $7.56 03/12/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, PLACEBO-CONTROLLED, RW No dispute reported 06/30/2026 637709391
Principal investigator 1 Ironwood Pharmaceuticals, Inc $160.00 03/01/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397327
Principal investigator 1 Amarin Pharma Inc. $5,748.75 02/26/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the effect of AMR101 on Cardiovascular Heath and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardio No dispute reported 06/30/2026 700952405
Principal investigator 1 Ironwood Pharmaceuticals, Inc $1,346.25 02/22/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
MCP-103-312 No dispute reported 06/30/2026 705397289
Principal investigator 1 Ironwood Pharmaceuticals, Inc $1,346.25 02/22/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
MCP-103-312 No dispute reported 06/30/2026 705397291
Principal investigator 1 Ironwood Pharmaceuticals, Inc $40,040.00 02/22/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
MCP-103-312 No dispute reported 06/30/2026 705397293
Principal investigator 1 Ironwood Pharmaceuticals, Inc $200.00 02/13/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
MCP-103-312 No dispute reported 06/30/2026 705397287
Principal investigator 1 Ironwood Pharmaceuticals, Inc $100.00 02/13/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397323
Principal investigator 1 Allergan Inc. $200.00 02/12/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH G
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 670024101
Principal investigator 1 Shire North American Group Inc $89.34 02/12/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, MAINTENANCE No dispute reported 06/30/2026 637708633
Principal investigator 1 Shire North American Group Inc $14,460.00 02/12/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, MAINTENANCE No dispute reported 06/30/2026 637708635
Principal investigator 1 Shire North American Group Inc $2,851.20 02/07/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, MAINTENANCE No dispute reported 06/30/2026 637708443
Principal investigator 1 Shire North American Group Inc $2,941.20 02/07/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, MAINTENANCE No dispute reported 06/30/2026 637708445
Principal investigator 1 Ironwood Pharmaceuticals, Inc $150.00 02/06/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
MCP-103-312 No dispute reported 06/30/2026 705397295
Principal investigator 1 Ironwood Pharmaceuticals, Inc $250.00 02/06/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397325
Principal investigator 1 Shire North American Group Inc $20.00 02/05/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, MAINTENANCE No dispute reported 06/30/2026 637708343
Principal investigator 1 Ironwood Pharmaceuticals, Inc $11,607.50 01/16/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397319
Principal investigator 1 Allergan Inc. $2,318.00 01/15/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH G
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 670016623
Principal investigator 1 Shire North American Group Inc $2,963.20 01/15/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, MAINTENANCE No dispute reported 06/30/2026 637707973
Principal investigator 1 Shire North American Group Inc $61.34 01/10/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, MAINTENANCE No dispute reported 06/30/2026 637707663
Principal investigator 1 Ironwood Pharmaceuticals, Inc $165.00 01/04/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
MCP-103-312 No dispute reported 06/30/2026 705397283
Principal investigator 1 Ironwood Pharmaceuticals, Inc $360.00 01/04/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
MCP-103-312 No dispute reported 06/30/2026 705397285
Principal investigator 1 Ironwood Pharmaceuticals, Inc $250.00 01/04/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL
C3718-302 No dispute reported 06/30/2026 705397321
Principal investigator 1 Allergan Inc. $500.00 01/03/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH G
OPEN-LABEL EXTENSION STUDY OF RELAMORELIN FOR THE TREATMENT OF DIABETIC GASTROPARESIS DG No dispute reported 06/30/2026 670013925
Principal investigator 1 Allergan Inc. $8,000.00 01/03/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH G
OPEN-LABEL EXTENSION STUDY OF RELAMORELIN FOR THE TREATMENT OF DIABETIC GASTROPARESIS DG No dispute reported 06/30/2026 670013931
Principal investigator 1 Adare Pharmaceuticals, Inc. $2,000.00 01/02/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
SP-1011-002 No dispute reported 06/30/2026 704669447
Principal investigator 1 Adare Pharmaceuticals, Inc. $2,000.00 01/02/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
SP-1011-002 No dispute reported 06/30/2026 704669449
Principal investigator 1 Adare Pharmaceuticals, Inc. $2,000.00 01/02/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
SP-1011-002 No dispute reported 06/30/2026 704669451
Principal investigator 1 Adare Pharmaceuticals, Inc. $300.00 01/02/2019 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
SP-1011-002 No dispute reported 06/30/2026 704669453